MX174467B - 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos - Google Patents

1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos

Info

Publication number
MX174467B
MX174467B MX9202168A MX9202168A MX174467B MX 174467 B MX174467 B MX 174467B MX 9202168 A MX9202168 A MX 9202168A MX 9202168 A MX9202168 A MX 9202168A MX 174467 B MX174467 B MX 174467B
Authority
MX
Mexico
Prior art keywords
triscarboximethyl
tetraazaciclodo
decan
substitute
analog compounds
Prior art date
Application number
MX9202168A
Other languages
English (en)
Inventor
Michael F Tweedle
Glen T Gaughan
James J Hagan
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/137,267 external-priority patent/US4885363A/en
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of MX174467B publication Critical patent/MX174467B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0476—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from monodendate ligands, e.g. sestamibi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic Table
    • C07F11/005—Compounds containing elements of Groups 6 or 16 of the Periodic Table compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds
    • C07F15/025—Iron compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/94—Bismuth compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/806—Electrical property or magnetic property
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX9202168A 1986-01-23 1992-05-11 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos MX174467B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82172586A 1986-01-23 1986-01-23
US4241687A 1987-04-24 1987-04-24
US07/137,267 US4885363A (en) 1987-04-24 1987-12-23 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs

Publications (1)

Publication Number Publication Date
MX174467B true MX174467B (es) 1994-05-17

Family

ID=27366124

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9202168A MX174467B (es) 1986-01-23 1992-05-11 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos

Country Status (2)

Country Link
US (4) US5474756A (es)
MX (1) MX174467B (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4009119A1 (de) * 1990-03-19 1991-09-26 Schering Ag 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
IT1269839B (it) * 1994-05-26 1997-04-15 Bracco Spa Coniugati di acidi biliari, loro derivati con complessi metallici e relativi usi
TW319763B (es) * 1995-02-01 1997-11-11 Epix Medical Inc
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6275726B1 (en) 1997-05-15 2001-08-14 Board Of Regents, The University Of Texas System Methods of enhanced light transmission through turbid biological media
FR2772025B1 (fr) * 1997-12-10 2000-03-03 Guerbet Sa Chelates metalliques de macrocycles polyaminocarboxyliques et leur application a l'imagerie par resonance magnetique
GB9726664D0 (en) * 1997-12-17 1998-02-18 Nycomed Imaging As Improvements in or relating to ultrasonography
US6537520B1 (en) * 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) * 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
WO2000035887A2 (en) 1998-12-18 2000-06-22 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2727746A1 (en) * 1998-12-18 2000-06-22 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US7685423B1 (en) * 2000-02-15 2010-03-23 Silverbrook Research Pty Ltd Validation protocol and system
JP3796412B2 (ja) * 2000-02-28 2006-07-12 キヤノン株式会社 撮像装置
US6565828B2 (en) 2000-04-07 2003-05-20 Bristol-Myers Squibb Company Macrocyclic chelants for metallopharmaceuticals
JP5448284B2 (ja) 2000-06-02 2014-03-19 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム エチレンジシステイン（ｅｃ）−薬物結合体
US7311893B2 (en) * 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
EP1390079A2 (en) 2000-11-20 2004-02-25 Board of Regents University of Texas System Paramagnetic metal ion-based macrocylic contrast agents
CA2429781C (en) * 2000-11-29 2011-01-11 Bracco International B.V. Linkable sialyl lewis x analogs
US6517814B2 (en) 2001-01-09 2003-02-11 Bristol-Myers Squibb Pharma Company Macrocyclic chelants useful for metallopharmaceuticals
BR0207521A (pt) 2001-02-23 2004-06-01 Bristol Myers Squibb Pharma Co Antagonistas rotulados de receptores de removedores macrófagos para a geração de imagens de aterosclerose e placa vulnerável
EP1293229B1 (en) * 2001-04-16 2004-07-07 Muradin Abubekirovich Kumakhov Radioscopy using k$g(a) gadolinium emission
WO2002096460A1 (en) * 2001-05-30 2002-12-05 Cornell Research Foundation, Inc. Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
ATE535258T1 (de) * 2001-06-01 2011-12-15 Cornell Res Foundation Inc Modifizierte antikörper gegen prostata- spezifisches membranantigen und ihre verwendungen
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
JP2005527474A (ja) * 2001-09-20 2005-09-15 コーネル リサーチ ファンデーション インコーポレーテッド 前立腺特異的膜抗原に特異的な結合剤を用いて、皮膚障害を治療するかまたは防止するための方法および組成物
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
WO2003074005A2 (en) 2002-03-01 2003-09-12 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
WO2003105762A2 (en) * 2002-06-14 2003-12-24 Actinium Pharmaceuticals Ltd. Treating disease using radium-225
US20040136998A1 (en) * 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
DE60323677D1 (de) * 2003-01-10 2008-10-30 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
US7611692B2 (en) * 2003-01-13 2009-11-03 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7922998B2 (en) * 2003-01-13 2011-04-12 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US20060239923A1 (en) * 2003-01-13 2006-10-26 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US8420050B2 (en) * 2003-01-13 2013-04-16 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US7850947B2 (en) * 2003-01-13 2010-12-14 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US20040208828A1 (en) * 2003-02-04 2004-10-21 Lutz Lehmann Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic acid and derivatives thereof, process for their production and use for the production of pharmaceutical agents
US20050214859A1 (en) 2003-03-03 2005-09-29 Dyax Corp. Peptides that specifically bind HGF receptor (cMet) and uses thereof
JP5139678B2 (ja) * 2003-07-24 2013-02-06 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
AU2004314112A1 (en) * 2003-12-24 2005-07-28 Bracco Imaging S.P.A. Improved gastrin releasing peptide compounds
WO2005070456A2 (en) * 2004-01-09 2005-08-04 Millennium Pharmaceuticals, Inc. Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
EP1610818A4 (en) * 2004-03-03 2007-09-19 Millennium Pharm Inc MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF
US7504088B2 (en) 2004-06-09 2009-03-17 Kereos, Inc. Lipophilic derivatives of chelate monoamides
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
GB0416857D0 (en) * 2004-07-29 2004-09-01 Ingenico Uk Ltd Electronic financial transactions
US20060210479A1 (en) * 2004-08-10 2006-09-21 Dow Global Technologies Inc. Targeting chelants and chelates
US20080279768A1 (en) * 2005-11-29 2008-11-13 Moore Dennis A Bifunctional Metal Chelating Conjugates
CA2643145C (en) * 2006-02-24 2014-04-29 Mallinckrodt Inc. Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates
JP2009530294A (ja) * 2006-03-15 2009-08-27 マリンクロット インコーポレイテッド 置換芳香族部分を有するキレート化接合体およびその誘導体
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
JP5345945B2 (ja) 2006-12-11 2013-11-20 ブラッコ・イメージング・ソシエタ・ペル・アチオニ フィブリン結合ペプチドおよびそのコンジュゲート
EP2192922A4 (en) 2007-09-17 2010-09-29 Univ California INTERNATIONALIZING HUMAN MONOCLONAL ANTIBODIES TO PROMOTE IN SITU ON PROSTATAZELLES
EP2147684A1 (en) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
US20120045393A1 (en) 2009-03-17 2012-02-23 Linder Karen E Lhrh-ii peptide analogs
CN105388287A (zh) 2011-03-11 2016-03-09 内布拉斯加大学董事委员会 冠状动脉疾病的生物标志物
WO2012136813A2 (en) 2011-04-07 2012-10-11 Universitetet I Oslo Agents for medical radar diagnosis
AU2012282678B2 (en) 2011-07-11 2016-03-03 California Institute Of Technology Akt-specific capture agents, compositions, and methods of using and making
WO2015171543A1 (en) 2014-05-05 2015-11-12 California Institute Of Technology Mutant akt-specific capture agents, compositions, and methods of using and making
US9913875B2 (en) 2015-03-16 2018-03-13 California Institute Of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
US20160287726A1 (en) * 2015-04-06 2016-10-06 The Trustees Of The University Of Pennsylvania Cationic contrast agents and methods of using the same
WO2017011769A2 (en) 2015-07-15 2017-01-19 California Institute Of Technology Il-17f-specific capture agents, compositions, and methods of using and making
US10946106B2 (en) 2015-11-30 2021-03-16 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
JP6991148B2 (ja) 2016-02-09 2022-01-12 ブラッコ・スイス・ソシエテ・アノニム セレクチン標的化のための組み換えキメラタンパク質
US20170319722A1 (en) 2016-04-04 2017-11-09 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
US10793532B2 (en) 2016-09-27 2020-10-06 Bayer Pharma Aktiengesellschaft Method for producing the crystalline form of modification a of calcobutrol
WO2018064597A1 (en) 2016-09-29 2018-04-05 Indi Molecular, Inc. Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
WO2018085375A1 (en) 2016-11-01 2018-05-11 Ohio State Innovation Foundation Methods for the iodination of biomolecules
EP3538551A4 (en) 2016-11-10 2020-11-11 Fortis Therapeutics, Inc. CD46 SPECIFIC EFFECTOR CELLS AND USES THEREOF
WO2018232345A1 (en) 2017-06-15 2018-12-20 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
WO2020093055A2 (en) 2018-11-02 2020-05-07 Indi Molecular, Inc. Peptide libraries with non-canonical amino acids
WO2020097531A1 (en) 2018-11-08 2020-05-14 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
CN109336833B (zh) * 2018-12-07 2020-09-25 嘉实（湖南）医药科技有限公司 一种1,4,7,10-四氮杂环十二烷-1,4,7-三乙酸的制备方法
US20200291391A1 (en) 2019-03-12 2020-09-17 Indi Molecular, Inc. Cross-linked epitopes and methods of use thereof
US12201679B2 (en) 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
US20220218834A1 (en) 2019-05-20 2022-07-14 Ohio State Innovation Foundation Apohemoglobin-haptoglobin complexes and methods of using thereof
US12216122B2 (en) 2019-05-20 2025-02-04 Regeneron Pharmaceuticals, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
US11414460B2 (en) 2019-07-19 2022-08-16 Institute For Systems Biology KRAS-specific capture agents, compositions, and methods of making and using
IL297806A (en) 2020-04-30 2022-12-01 Sairopa B V Anti-cd103 antibodies
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
US11484604B2 (en) 2020-08-07 2022-11-01 Fortis Therapeutics, Inc. Immunoconjugates targeting CD46 and methods of use thereof
EP4196174A4 (en) * 2020-08-11 2025-01-29 Inventure, LLC MACROCYCLIC CONTRAST AGENTS WITH REDUCED METASTABLE COMPLEX
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
CA3227425A1 (en) 2021-07-26 2023-02-02 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound
WO2025245032A1 (en) 2024-05-20 2025-11-27 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201472A (en) * 1958-12-02 1965-08-17 Geigy Chem Corp Tertiary-amino-alkylated primary amines
US4156683A (en) * 1973-03-26 1979-05-29 Schering Corporation Complexes of macrocyclic compounds
US4085106A (en) * 1976-01-07 1978-04-18 E. I. Du Pont De Nemours And Company Bicyclic and tricyclic trisaminomethanes
JPS53144593A (en) * 1977-05-19 1978-12-15 Iwao Tabuse Alklycyclum
JPS53144592A (en) * 1977-05-19 1978-12-15 Tabuse Iwao 122alkyll1*4*7*100tetrazacyclotridecane
US4190462A (en) * 1978-07-04 1980-02-26 Shell Oil Company Dissolving barium sulfate scale with aqueous solutions of salts of carboxymethyl monocyclic macrocyclic polyamines
GB2108106B (en) * 1978-07-04 1983-09-01 Shell Int Research Novel macrocyclic compounds and salts thereof useful for dissolving barium sulphate scale
US4543213A (en) * 1978-07-24 1985-09-24 The United States Of America As Represented By The United States Department Of Energy Process for preparing 2,3-dihydroxybenzoic acid amides of tetraazaalkanes and cycloalkanes
NO149961C (no) * 1981-06-01 1984-07-25 Borregaard Ind Fremgangsmaate for fremstilling av n-(2-hydroksyetyl)-derivater av makrocykliske polyaminer, inneholdende flere nitrogenatomer i 1,4-forhold i ringen
DE3129906C3 (de) * 1981-07-24 1996-12-19 Schering Ag Paramagnetische Komplexsalze, deren Herstellung und Mittel zur Verwendung bei der NMR-Diagnostik
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
NL194579C (nl) * 1983-01-21 2002-08-05 Schering Ag Diagnostisch middel.
DE3316703A1 (de) * 1983-05-04 1984-11-08 Schering AG, 1000 Berlin und 4709 Bergkamen Orales kontrastmittel fuer die kernspintomographie und dessen herstellung
JPS59202869A (ja) * 1983-05-04 1984-11-16 Sanyo Electric Co Ltd 印字制御装置
FR2550449B1 (fr) * 1983-08-12 1986-01-31 Commissariat Energie Atomique Agents de relaxation specifiques d'organes ou de pathologies, utilisables pour modifier les contrastes en imagerie medicale par resonance magnetique nucleaire
US4639365A (en) * 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
US4826673A (en) * 1985-01-09 1989-05-02 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
US4899755A (en) * 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US4885363A (en) * 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
IT1213029B (it) * 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
GB8603537D0 (en) * 1986-02-13 1986-03-19 Parker D Conjugate compound
FR2596992B1 (fr) * 1986-04-11 1988-12-16 Guerbet Sa Sel de lysine du complexe gadolinium-dota et ses applications au diagnostic

Also Published As

Publication number Publication date
US6143274A (en) 2000-11-07
US5846519A (en) 1998-12-08
US5474756A (en) 1995-12-12
US5674470A (en) 1997-10-07

Similar Documents

Publication Publication Date Title
MX174467B (es) 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
DE3688842D1 (de) Elastische beinwinde und deren herstellung.
IT1205010B (it) Tetraidronaftalin-derivati e indan-derivati
DE3769458D1 (de) Physiologisch wirksame und naehrende zusammensetzung.
ES2025059B3 (es) Diseño de gasificacion y dosificacion.
TR25164A (tr) INTEKTISID ÖZELLIKTE N'-SüBSTITüENTLI-N,N-DIACIL- HIDRAZINLER
PT87554A (pt) Didinfecting and sterilizing composition
TR22500A (tr) Diflufenikan'in kullanilmasini ihtiva eden herbisidal usul
DE3762960D1 (de) Rollstein und aus rollsteinen zusammengesetzte rollbahn.
FI880876A0 (fi) Foerbaettringar i anordningar foer att injektera aemnen in i vaetskor.
DE3766441D1 (de) Anilinotriazine und deren verwendung.
FI883607A0 (fi) Effektivt foerfarande foer in vitro-in vivo-produktion av minirotknoelar av potatis.
FI881648A0 (fi) Shampookoostumuksia
IT207822Z2 (it) Contenitore 2000
FI870848A0 (fi) Anordning foer dragning av kablar in i skyddsroer foer kablar.
KR870015914U (ko) 의자
FI851796A0 (fi) Kamflaenskonstruktion foer fastsaettning av tvao in i varandra placerbara roerformiga stycken.
SE8604507D0 (sv) Mutter- och skruvdragare
SE8603890D0 (sv) Underbenskydd
DK113087D0 (da) 3 i een- baad
TR23461A (tr) Insektisid oezellikte suebstituee edilmis inolazoller
IT1214035B (it) Perfezionamenti nelle chiusure lampo
DK165087D0 (da) Vendestol
IT8729511V0 (it) Perfezionamenti nelle chiusure lampo
BR8704976A (pt) Modem analogico its 26

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees